Compare BIO-TECHNE Corp (TECH) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs T-Mobile Us Inc — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while T-Mobile Us Inc trades at $149.55 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 16.2× BIO-TECHNE Corp's market cap, and T-Mobile Us Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and T-Mobile Us Inc for 84 Days on average.
| TECH | TMUS | |
|---|---|---|
Market Cap | $11.36B | $183.76B |
Volume | 5,390,331 | 4,294,650 |
Sector | Health | Media |
52-Week High | $72.61 | $230.06 |
52-Week Low | $43.31 | $161.73 |
Typical Hold Time | 63 Days | 84 Days |
Enterprise Value | $11.39B | $300.37B |
Dividend Yield | 0.44% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
T-Mobile US (TMUS) trades at $167.62, up 1.02% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $88.31B revenue in 2025, 11.45% net margin, and consistent earnings beats in recent quarters. Recent developments include a 15% dividend increase to $1.17 per share and participation in a joint venture with AT&T and Verizon to expand satellite connectivity.
TMUS presents a compelling investment case with strong analyst support (79.6% buy ratings) and a $231.10 price target representing 38% upside. However, risks include $84.6B debt load, increasing debt-to-asset ratio (39.35% in 2025), and competitive pressures in the wireless industry. The stock offers growth potential through 5G expansion and AI-driven network improvements while maintaining dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
